发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
Quetiapine: a new option in bipolar depression 奎硫平:双相抑郁症的新选择
Future Prescriber Pub Date : 2009-12-24 DOI: 10.1002/fps.56
Eleni Palazidou MD, PhD, MRCP, FRCPsych
{"title":"Quetiapine: a new option in bipolar depression","authors":"Eleni Palazidou MD, PhD, MRCP, FRCPsych","doi":"10.1002/fps.56","DOIUrl":"10.1002/fps.56","url":null,"abstract":"<p>Bipolar disorder is a condition characterised by periods of depression, mania or depressive and manic symptoms appearing together. Depression is the predominant symptom and is often responsible for poor quality of life. The condition is treatable, but poor compliance is a major problem. Pharmacological treatments include lithium (although it has poor efficacy in depression), valproate and olanzapine (which can cause metabolic syndrome). In this article, Dr Palazidou considers quetiapine, a second-generation antipsychotic agent, for the treatment of bipolar depression and mania, as well as mixed affective states in bipolar I disorder. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75257998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Comparing notes: cancer leaders discuss the latest advances 交换意见:癌症领袖讨论最新进展
Future Prescriber Pub Date : 2009-12-24 DOI: 10.1002/fps.58
{"title":"Comparing notes: cancer leaders discuss the latest advances","authors":"","doi":"10.1002/fps.58","DOIUrl":"https://doi.org/10.1002/fps.58","url":null,"abstract":"<p>New data from different tumour types highlight similarities and differences for specialists, as presented at the Cancer Congress Update meeting held in London, July 2009</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"21-23"},"PeriodicalIF":0.0,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.58","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137881672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New developments in multiple sclerosis and pain management 多发性硬化症和疼痛管理的新进展
Future Prescriber Pub Date : 2009-12-24 DOI: 10.1002/fps.59
Kerry Laundon
{"title":"New developments in multiple sclerosis and pain management","authors":"Kerry Laundon","doi":"10.1002/fps.59","DOIUrl":"10.1002/fps.59","url":null,"abstract":"<p>Promising studies were reported at the 25th congress of the European Committee for Treatment and Research in MS (ECTRIMS), held on 9-12 September 2009 in Düsseldorf, Germany, while data on a new treatment for chronic low back pain was presented at the 6th Triennial congress of the European Federation of Chapters (EFIC) of the International Association for the Study of Pain (IASP), held on 9-12 September 2009 in Lisbon, Portugal. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"24-26"},"PeriodicalIF":0.0,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.59","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81120413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Certolizumab pegol: a new option for rheumatoid arthritis Certolizumab pegol:类风湿关节炎的新选择
Future Prescriber Pub Date : 2009-12-24 DOI: 10.1002/fps.57
Margaret HY Ma MBBS, BSc, MRCP, MSc, Ernest HS Choy MD FRCP
{"title":"Certolizumab pegol: a new option for rheumatoid arthritis","authors":"Margaret HY Ma MBBS, BSc, MRCP, MSc,&nbsp;Ernest HS Choy MD FRCP","doi":"10.1002/fps.57","DOIUrl":"10.1002/fps.57","url":null,"abstract":"<p>Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.57","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77626749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-TNF-alpha drugs - moving into the mainstream? 抗tnf - α药物——进入主流?
Future Prescriber Pub Date : 2009-12-24 DOI: 10.1002/fps.55
Tina Ding MSc, MRCP, Chris Deighton BMedSci, MD, FRCP
{"title":"Anti-TNF-alpha drugs - moving into the mainstream?","authors":"Tina Ding MSc, MRCP,&nbsp;Chris Deighton BMedSci, MD, FRCP","doi":"10.1002/fps.55","DOIUrl":"10.1002/fps.55","url":null,"abstract":"<p>Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.55","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74084239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Future directions in antiplatelet therapy: efficacy versus safety 抗血小板治疗的未来方向:疗效与安全性
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.52
Nadzeya Kuzniatsova, Eduard Shantsila MD, Gregory YH Lip MD, FRCP
{"title":"Future directions in antiplatelet therapy: efficacy versus safety","authors":"Nadzeya Kuzniatsova,&nbsp;Eduard Shantsila MD,&nbsp;Gregory YH Lip MD, FRCP","doi":"10.1002/fps.52","DOIUrl":"10.1002/fps.52","url":null,"abstract":"<p>An improved understanding of the underlying mechanisms of platelet activation and thrombogenesis has led to the discovery of new antiplatelet agents. Various clinical studies have investigated the effectiveness of these new agents in comparison with ‘traditional’ antiplatelet drugs. The problem with this approach is that enhanced antiplatelet activity may result in excessive bleeding complications. Consequently, the challenge is to ascertain the fine balance between optimal efficacy and safety for future antiplatelet drugs and their combinations. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84645793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of prostate cancer: future treatment approaches 前列腺癌的管理:未来的治疗方法
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.49
Professor Malcolm Mason
{"title":"Management of prostate cancer: future treatment approaches","authors":"Professor Malcolm Mason","doi":"10.1002/fps.49","DOIUrl":"10.1002/fps.49","url":null,"abstract":"<p>Prostate cancer is now the most commonly diagnosed cancer in men. This may reflect a true increase in the incidence of the disease, but a component of it is certainly related to increased detection rates due to opportunistic prostate specific antigen (PSA) testing. In this article, Professor Malcolm Mason reviews the current treatment of prostate cancer and considers promising future treatment options, including the possibility of prevention as suggested by recent studies. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"9-12"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84778658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Reports on rheumatoid arthritis, gout and fibromyalgia from the 10th Annual Congress of the European League Against Rheumatism (EULAR), held on 10–13 June 2009 in Copenhagen, Denmark 2009年6月10日至13日在丹麦哥本哈根举行的欧洲抗风湿病联盟(EULAR)第10届年会上关于类风湿性关节炎、痛风和纤维肌痛的报告
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.54
Jill Stein
{"title":"Reports on rheumatoid arthritis, gout and fibromyalgia from the 10th Annual Congress of the European League Against Rheumatism (EULAR), held on 10–13 June 2009 in Copenhagen, Denmark","authors":"Jill Stein","doi":"10.1002/fps.54","DOIUrl":"10.1002/fps.54","url":null,"abstract":"","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"25-26"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78004794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer, arthritis and gout: reports from ASCO and EULAR 肺癌、关节炎和痛风:来自ASCO和EULAR的报告
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.53
Sue Lyon
{"title":"Lung cancer, arthritis and gout: reports from ASCO and EULAR","authors":"Sue Lyon","doi":"10.1002/fps.53","DOIUrl":"10.1002/fps.53","url":null,"abstract":"<p>The second most common cancer diagnosed in the UK, lung cancer, is also the most deadly. Over twothirds of patients present with advanced disease, and at present only 7% survive for at least five years after diagnosis.<sup>1</sup> New hope is offered by studies presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), held on 28 May–2 June in Orlando, USA Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"24-25"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75375506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Saxagliptin: a new option for the management of type 2 diabetes 沙格列汀:治疗2型糖尿病的新选择
Future Prescriber Pub Date : 2009-08-13 DOI: 10.1002/fps.50
Marc Evans MRCP, MD
{"title":"Saxagliptin: a new option for the management of type 2 diabetes","authors":"Marc Evans MRCP, MD","doi":"10.1002/fps.50","DOIUrl":"10.1002/fps.50","url":null,"abstract":"<p>Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present a new approach to disease management. Over recent years, several new drugs have entered the marketplace, and NICE have recently issued guidance on how best to incorporate these new drugs into treatment regimens. In this article, Marc Evans reviews saxagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, and considers its potential clinical use. Copyright © 2009 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"13-17"},"PeriodicalIF":0.0,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74212647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信